Two Sigma Investments LP Acquires 127,219 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Two Sigma Investments LP increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 71.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 306,272 shares of the company's stock after buying an additional 127,219 shares during the period. Two Sigma Investments LP owned 0.36% of CRISPR Therapeutics worth $12,055,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Intellectus Partners LLC boosted its holdings in CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after buying an additional 250 shares during the last quarter. Farrow Financial Inc. raised its position in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after acquiring an additional 270 shares during the period. Kestra Private Wealth Services LLC boosted its stake in CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after acquiring an additional 310 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after purchasing an additional 372 shares during the period. Finally, Horizon Kinetics Asset Management LLC increased its stake in CRISPR Therapeutics by 4.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock valued at $420,000 after purchasing an additional 443 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at $7,673,353.80. This represents a 5.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,021 shares of company stock valued at $594,771. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded up $0.71 during trading hours on Tuesday, reaching $37.57. 2,051,305 shares of the company were exchanged, compared to its average volume of 1,692,435. The business has a 50 day moving average of $36.95 and a 200 day moving average of $41.77. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market capitalization of $3.24 billion, a P/E ratio of -8.60 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the firm posted ($1.43) earnings per share. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of recent analyst reports. Barclays reduced their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Morgan Stanley boosted their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Citigroup decreased their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. Finally, JMP Securities reissued a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.